Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents

Bioconjugate Chemistry

Volumn 18, Issue 4, 2007, Pages 1266-1279

  Harris, Thomas D ^a   Cheesman, Edward ^a   Harris, Anthony R ^a   Sachleben, Richard ^a,b   Edwards, D Scott ^a   Liu, Shuang ^a,c   Bartis, Judit ^a,d   Ellars, Charles ^a,e   Onthank, Dave ^a   Yalamanchili, Padmaja ^a   Heminway, Stuart ^a,f   Silva, Paula ^a   Robinson, Simon ^a   Lazewatsky, Joel ^a   Rajopadhye, Milind ^a,g   Barrett, John ^a,h  

^a BRISTOL MYERS SQUIBB   (United States)

^b Momenta Pharmaceuticals Inc   (United States)

^c PURDUE UNIVERSITY   (United States)

^d ARQULE INC   (United States)

^e AEA Technology QSA   (United States)

^f ASTRAZENECA   (United Kingdom)

^g VisEn Medical   (United States)

^h A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELLS;

DIVALENTS; ENDOTHELIAL-CELLS; IMAGING AGENT; INTEGRIN RECEPTORS; PEPTIDOMIMETICS; POST INJECTION; RECEPTOR ANTAGONISTS; THERAPEUTIC INDEX; TUMOR UPTAKE; VITRONECTIN;

TUMORS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; INDIUM 111; INTEGRIN RECEPTOR; LUTETIUM 177; QUINOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TA 138; TA 138 IN 111; TA 138 Y 90; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR BLOCKING AGENT; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER MODEL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ISOTOPE LABELING; MOUSE; NONHUMAN; ONCOGENE NEU; RECEPTOR AFFINITY; SCINTIMAMMOGRAPHY;

EID: 34547159682     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc070002+     Document Type: Article

References (50)

1. van der Flier, A., and Sonnenberg, A. (2001) Function and interactions of integrins. Cell Tissue Res. 305, 285-298.
2. Mizeiewski, G. J. (1999) Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 222, 124-138.
3. Hood, J. D., and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100.
4. Tucker, G. C. (2002) Inhibitors of integrins. Curr. Opin. Pharm. 2, 394-402.
5. Jin, H., and Varner, J. (2004) Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565.
6. 3 expression on tumor-associated vessels of human carcinomas. Int. J. Cancer 71, 320-324.
7. v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Amer. J. Pathol. 151, 975-983.
8. Cairns, R. A., Khokha, R., and Hill, R. P. (2003) Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med. 3, 659-671.
9. Felding-Habermann, B. (2003) Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis 20, 203-213.
10. Mizejewski, G. J. (1999) Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 222, 124-138.
11. 3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 5, 127-135.
12. 3. Anticancer Res. 19, 1529-1532.
13. 3 is modulated by a focal adhesion kinase pathway. Cancer Res. 59, 1655-1664.
14. 3. Expert Opin. Ther. Patents 12, 1009-1021.
15. Tucker, G. C. (2003) Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Invest. Drugs 4, 722-731.
16. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
17. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822.
18. 5 integrin receptor antagonist. Cancer Res. 61, 2232-2238.
19. 3 Integrin in angiogenesis and restenosis. Drug News Perspect. 14, 143-150.
20. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem. 15, 61-69.
21. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 31, 179-189.
22. 64Cu-Labeled RGD peptide for imaging breast cancer in mice with microPET. Bioconjugate Chem. 15, 41-49.
23. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Radjopadhye, M., Corstens, F. H. M., and Boerman, O. C. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 17, 641-646.
24. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151.
25. 3 integrin receptor antagonists. Nucl. Med. Biol. 33, 953-961.
26. 3 expression. Nucl. Med. Biol. 33, 945-952.
27. 3 expression in man. Clin. Cancer Res. 12, 3942-3949.
28. Haubner, R., and Wester, H.-J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des. 10, 1439-1455.
29. 3-Integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging 33, S54-S63.
30. 3 targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
31. 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
32. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: Potential tumor imaging agents. Bioconjugate Chem. 17, 1294-1313.
33. 3. J. Nucl. Med. 41, 259P.
34. 3 integrin directed therapeutics. Bioconjugate Chem. 13, 128-135.
35. 3 expression in living mice. Bioconjugate Chem. 16, 1433-1441.
36. 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96-104.
37. Vagner, J., Handl, H. L., Gillies, R. J., and Hruby, V. R. (2004) Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of α-MSH. Biorg. Med. Chem. Lett. 14, 211-215.
38. Tweedle, M. F. (2006) Adventures in multivalency: The Harry S. Fischer Memorial Lecture, CMR 2005; Evian, France. Contrast Media Mol. Imaging 1, 2-9.
39. Harris, T. D., Barrett, J. A., Carpenter, A. P., and Rajopadhye, M. (2003) Vitronectin Receptor Antagonist Pharmaceuticals. U.S. Patent 6,511,649.
40. Gerhardt, J. and Nicholson, G. J. (1994) Unambiguous determination of the optical purity of peptides via GC-MS. Peptides: Chemistry, Structure, and Biology (Hodges, R. S. and Smith, J. A., Eds) pp 241-243, Escom, Leiden.
41. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjugate Chem. 17, 1294-1313.
42. 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. Bioconjugate Chem. 14, 1030-1037.
43. 3. J. Med. Chem. 43, 27-40.
44. Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 37, 2754-2794.
45. Handl, H. L., Vagner, J., Han, H., Mash, E., Hruby, V. J., and Gillies, R. J. (2004) Hitting multiple targets with multimeric ligands. Exp. Opin. Ther. Targets 8, 565-586.
46. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta, 92, 317-327.
47. 5. J. Virol. 73, 6759-6768.
48. 3. Science 294, 339-345.
49. 3 receptor antagonist: different but biologically equivalent. Bioconjugate Chem. 15, 235-241.
50. Stabin, M. G., Sparks, R. B., and Crowe, E. (2005) OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 46, 1023-1027.